| Pharmaceutical Information |
| Drug Name |
Bleomycin |
| Drug ID |
BADD_D00280 |
| Description |
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. |
| Indications and Usage |
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01DC01 |
| DrugBank ID |
DB00290
|
| KEGG ID |
D07535
|
| MeSH ID |
D001761
|
| PubChem ID |
5460769
|
| TTD Drug ID |
D06UVD
|
| NDC Product Code |
0143-9241; 69097-364; 0703-3155; 0143-9240; 16714-908; 61703-332; 61703-323; 16714-886; 0409-0332; 70121-1567; 0409-0323; 0703-3154 |
| UNII |
40S1VHN69B
|
| Synonyms |
Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina |
|
| Chemical Information |
| Molecular Formula |
C55H84N17O21S3+ |
| CAS Registry Number |
11056-06-7 |
| SMILES |
CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)
OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6
=NC(=CS6)C(=O)NCCC[S+](C)C)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
